Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ASNB
EKIMAS
$0.61
$0.56
$0.55
$1.75
$4.93M0.373,162 shsN/A
Calmare Therapeutics Incorporated stock logo
CTTC
Calmare Therapeutics
$0.00
$0.00
$0.02
N/AN/AN/AN/A
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
$0.00
$0.00
$0.01
N/AN/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
$4.41
+1.8%
$3.87
$2.70
$11.55
$8.60M2.2628,700 shs7,134 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ASNB
EKIMAS
0.00%0.00%0.00%+12.96%-24.69%
Calmare Therapeutics Incorporated stock logo
CTTC
Calmare Therapeutics
0.00%0.00%0.00%0.00%0.00%
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
0.00%0.00%0.00%0.00%0.00%
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
+1.85%+20.82%+8.89%+42.26%-60.77%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ASNB
EKIMAS
N/AN/AN/AN/AN/AN/AN/AN/A
Calmare Therapeutics Incorporated stock logo
CTTC
Calmare Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
N/AN/AN/AN/AN/AN/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ASNB
EKIMAS
N/AN/AN/AN/A
Calmare Therapeutics Incorporated stock logo
CTTC
Calmare Therapeutics
N/AN/AN/AN/A
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
N/AN/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ASNB
EKIMAS
N/AN/AN/AN/A$0.03 per shareN/A
Calmare Therapeutics Incorporated stock logo
CTTC
Calmare Therapeutics
N/AN/AN/AN/AN/AN/A
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
N/AN/AN/AN/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
$5.90M1.49N/AN/A$13.18 per share0.33

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ASNB
EKIMAS
-$290KN/A0.00N/AN/A-7,902.31%-5,274.01%N/A
Calmare Therapeutics Incorporated stock logo
CTTC
Calmare Therapeutics
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
N/AN/A0.00N/AN/AN/AN/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
-$6.53M-$6.23N/AN/A-110.64%-31.31%-29.32%5/1/2024 (Estimated)

Latest NURO, MDIT, ASNB, and CTTC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/22/2024Q4 2023
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/A-$1.43-$1.43-$1.43N/A$1.32 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ASNB
EKIMAS
N/AN/AN/AN/AN/A
Calmare Therapeutics Incorporated stock logo
CTTC
Calmare Therapeutics
N/AN/AN/AN/AN/A
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
N/AN/AN/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ASNB
EKIMAS
N/A
0.12
0.12
Calmare Therapeutics Incorporated stock logo
CTTC
Calmare Therapeutics
N/AN/AN/A
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
N/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/A
16.80
15.55

Ownership

Institutional Ownership

CompanyInstitutional Ownership
ASNB
EKIMAS
N/A
Calmare Therapeutics Incorporated stock logo
CTTC
Calmare Therapeutics
N/A
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
N/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
19.40%

Insider Ownership

CompanyInsider Ownership
ASNB
EKIMAS
7.80%
Calmare Therapeutics Incorporated stock logo
CTTC
Calmare Therapeutics
17.50%
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
85.40%
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
7.30%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
ASNB
EKIMAS
115.80 million5.35 millionNot Optionable
Calmare Therapeutics Incorporated stock logo
CTTC
Calmare Therapeutics
7N/AN/ANot Optionable
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
69N/AN/ANot Optionable
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
261.99 million1.84 millionNot Optionable

NURO, MDIT, ASNB, and CTTC Headlines

SourceHeadline
StockNews.com Begins Coverage on NeuroMetrix (NASDAQ:NURO)StockNews.com Begins Coverage on NeuroMetrix (NASDAQ:NURO)
americanbankingnews.com - April 26 at 2:24 AM
NeuroMetrix, Inc.s (NASDAQ:NURO) CEO Might Not Expect Shareholders To Be So Generous This YearNeuroMetrix, Inc.'s (NASDAQ:NURO) CEO Might Not Expect Shareholders To Be So Generous This Year
finance.yahoo.com - April 24 at 9:11 AM
NeuroMetrix appoints new board director, ends ATM facilityNeuroMetrix appoints new board director, ends ATM facility
investing.com - April 20 at 6:57 PM
NeuroMetrix Rises 18% After Announcement Of Shareholder Value Enhancement StepsNeuroMetrix Rises 18% After Announcement Of Shareholder Value Enhancement Steps
markets.businessinsider.com - April 19 at 2:51 PM
NeuroMetrix, Inc.: NeuroMetrix Announces Steps Taken to Enhance Shareholder ValueNeuroMetrix, Inc.: NeuroMetrix Announces Steps Taken to Enhance Shareholder Value
finanznachrichten.de - April 19 at 9:50 AM
NeuroMetrix Announces Steps Taken to Enhance Shareholder ValueNeuroMetrix Announces Steps Taken to Enhance Shareholder Value
globenewswire.com - April 19 at 8:00 AM
NeuroMetrix (NASDAQ:NURO) Coverage Initiated by Analysts at StockNews.comNeuroMetrix (NASDAQ:NURO) Coverage Initiated by Analysts at StockNews.com
americanbankingnews.com - April 18 at 2:30 AM
NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral NeuropathyNeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy
globenewswire.com - March 14 at 9:00 AM
NeuroMetrix, Inc.: NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell FibromyalgiaNeuroMetrix, Inc.: NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell Fibromyalgia
finanznachrichten.de - March 13 at 10:19 PM
NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® FibromyalgiaNeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® Fibromyalgia
globenewswire.com - March 13 at 9:00 AM
Echo Lake Capital Issues Top Ten List of Reasons Why Shai Gozani, CEO of Neurometrix Inc., Should Be FiredEcho Lake Capital Issues Top Ten List of Reasons Why Shai Gozani, CEO of Neurometrix Inc., Should Be Fired
accesswire.com - March 12 at 8:00 AM
RS Fund Management LLC: RS FUND LP Calls for Immediate Action and Capital Return in Neurometrix, Inc.RS Fund Management LLC: RS FUND LP Calls for Immediate Action and Capital Return in Neurometrix, Inc.
finanznachrichten.de - March 8 at 2:12 PM
RS FUND LP Calls for Immediate Action and Capital Return in Neurometrix, Inc.RS FUND LP Calls for Immediate Action and Capital Return in Neurometrix, Inc.
finance.yahoo.com - March 8 at 2:12 PM
Echo Lake Capital Calls for the Liquidation of Neurometrix, Inc.Echo Lake Capital Calls for the Liquidation of Neurometrix, Inc.
accesswire.com - March 4 at 8:00 AM
Google releases new open LLMs, Rivian lays off staff and Signal rolls out usernamesGoogle releases new open LLMs, Rivian lays off staff and Signal rolls out usernames
au.lifestyle.yahoo.com - February 25 at 9:19 AM
NeuroMetrix Full Year 2023 Earnings: US$6.08 loss per share (vs US$4.96 loss in FY 2022)NeuroMetrix Full Year 2023 Earnings: US$6.08 loss per share (vs US$4.96 loss in FY 2022)
finance.yahoo.com - February 24 at 12:41 PM
NeuroMetrix, Inc. (NASDAQ:NURO) Q4 2023 Earnings Call TranscriptNeuroMetrix, Inc. (NASDAQ:NURO) Q4 2023 Earnings Call Transcript
finance.yahoo.com - February 23 at 4:00 PM
NeuroMetrix, Inc.: NeuroMetrix Reports Q4 and Full Year 2023 Business HighlightsNeuroMetrix, Inc.: NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights
finanznachrichten.de - February 22 at 8:37 AM
NeuroMetrix Reports Q4 and Full Year 2023 Business HighlightsNeuroMetrix Reports Q4 and Full Year 2023 Business Highlights
finance.yahoo.com - February 22 at 8:37 AM
NeuroMetrix Reports Q4 and Full Year 2023 Business HighlightsNeuroMetrix Reports Q4 and Full Year 2023 Business Highlights
globenewswire.com - February 22 at 7:00 AM
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference CallNeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference Call
finance.yahoo.com - February 15 at 11:31 AM
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference CallNeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference Call
globenewswire.com - February 15 at 9:00 AM
NeuroMetrix, Inc.: NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder ValueNeuroMetrix, Inc.: NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value
finanznachrichten.de - February 13 at 4:30 PM
NeuroMetrix Plans Strategic Options To Promote Growth, Maximize Shareholder Value; Stock DropsNeuroMetrix Plans Strategic Options To Promote Growth, Maximize Shareholder Value; Stock Drops
markets.businessinsider.com - February 13 at 4:30 PM

New MarketBeat Followers Over Time

Company Descriptions

EKIMAS

OTCMKTS:ASNB
EKIMAS Corp. engages in the development of polymer materials, which provide characteristics in the design and development of medical devices. Its biomaterials are used in devices that are designed for treating a range of anatomical sites and disease states. The firm's products include ChronoFlex, ChronoSil, HydroMed, HydroThane, and PolyBlend. The company was founded in 1993 and is headquartered in Las Vegas, NV.
Calmare Therapeutics logo

Calmare Therapeutics

OTCMKTS:CTTC
Calmare Therapeutics Incorporated, a medical device company, develops and commercializes products and technologies for chronic neuropathic pain and wound care affliction patients in the United States. Its flagship medical device is Calmare Pain Therapy Device, a non-invasive and non-addictive modality for the treatment of chronic and neuropathic pain. The company was formerly known as Competitive Technologies, Inc. and changed its name to Calmare Therapeutics Incorporated in August 2014. Calmare Therapeutics Incorporated was founded in 1968 and is based in Fairfield, Connecticut.
Medite Cancer Diagnostics logo

Medite Cancer Diagnostics

OTCMKTS:MDIT
Medite Cancer Diagnostics, Inc. operates as a medical technology company. It develops, manufactures, and markets molecular biomarkers, medical devices, and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions and related diseases. The company offers USE 33, an ultrasonic decalcification instrument that automatically runs the process under controlled temperatures; TPC 15 Duo and Trio, a tissue processing instrument; TES 99 and TES Valida cooling units; and M530, A550, M380 microtomes for tissue sectioning. It also provides M630, a freezing microtome; TST44, a robotic multi-staining system; COT 20, a linear staining system; and RCM 9000, ACS 720, and TWISTER robotic coverslippers. In addition, the company develops SoftKit device for the self-collection of a sample that can be evaluated to provide an assessment of the health of the entire female genital tract. It sells its products through direct sales and distributors in the United States, China, Europe, and North Africa. The company serves histology and cytology laboratories associated with hospitals or research institutions, and independent laboratories. Medite Cancer Diagnostics, Inc. is based in Orlando, Florida.
NeuroMetrix logo

NeuroMetrix

NASDAQ:NURO
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.